

Evolution of COVID-19 cases in selected low- and middle-income countries: past the herd immunity peak?

Axel S. Lexmond^{1*}, Carlijn J.A. Nouwen^{2*†}, Othmane Fourtassi² and J. Paul Callan^{2*†}

¹ Department of Engineering, University of Pretoria, South Africa

² Personal capacity

* These authors contributed equally to this work.

† Corresponding authors.

Email: nouwencarlijn@gmail.com (C.J.A.N.); paul_callan@post.harvard.edu (J.P.C.)

25 September 2020; revised 1 October 2020.


COVID-19 cases have peaked and declined rapidly in many low- and middle-income countries in recent months, in some cases after control measures were relaxed. For 11 such countries, the hypothesis that these countries have reached herd immunity warrants serious consideration. The Reed-Frost model, perhaps the simplest description for the evolution of cases in an epidemic, with only a few constant parameters, fits the observed case data remarkably well, and yields parameter values that are reasonable. The model results give infection rates of 45% and 79%, above the herd immunity thresholds for each country (under current social distancing conditions). Reproduction numbers range between 1.4 and 2.0, indicating that epidemic curves were “flattened” but not “suppressed”. Between 0.05% and 2.86% of cases have been detected according to the estimates – values which are consistent with findings from serological and T-cell immunity studies. Overall infection fatality ratios for two of three countries studied are lower than expected from reported infection fatality ratios by age (which are based on studies of several high-income countries). COVID-19 may have lower age-specific fatality risks in some countries, due to differences in immune-response, prior exposure to coronaviruses, disease characteristics or other factors. We find that the herd immunity hypothesis would not have fit the evolution of reported cases in several European countries, even just after the initial peaks – and subsequent resurgences of cases obviously prove that those countries have infection rates well below herd immunity levels. Our hypothesis that the 11 countries we studied have reached herd immunity should now be tested further, through serological and T-cell-immunity studies.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Introduction

Figure 1, based on a similar one produced by researchers at Imperial College London¹, illustrates how case numbers are expected to evolve during an epidemic under different conditions. The green curve shows expected cases for an uncontrolled outbreak. This curve has three main features: initial exponential growth in new cases, followed by a single peak as the cumulative cases reach a herd immunity threshold, and an exponential decline in new cases. The herd immunity threshold is determined by the effective basic reproduction number (R_{0_e})² through the formula $1-1/R_{0_e}$. The red curve shows expected cases when governments and people take measures to control disease spread, but those measures are not sufficient to reduce the effective basic reproduction number (R_{0_e})² below 1. The red curve displays largely the same features as the green – disease spread is only halted by herd immunity – but the curve is “flattened”, with cases spread out more over time and fewer cases at the peak. The blue curve shows the evolution of cases when containment measures are sufficient to bring R_{0_e} below 1. The curve is “crushed”; the initial exponential growth in case numbers is halted and cases decline (at a slower rate than for the green or red curves). In this case, because most people are not immune to the disease, it is possible for the disease to return if containment measures later allow R_{0_e} to increase above 1, as shown in the dashed part of the blue curve in Figure 1.

Figure 1. Typical disease outbreak curves in different scenarios.¹




Patterns in reported cases

Reported cases in several low- and middle-income countries (LMICs) have evolved in a manner that is very similar to the red and green curves of Figure 1. We show the 7-day rolling average of reported new cases for 11 such countries in Figure 2. Other countries show similar patterns; we have chosen to study a subset with the clearest similarities to expected outbreak curves for which R_{0_e} remains above 1. In all these countries, the reported cases have (1) grown exponentially, (2) reached a single clear peak


and (3) declined exponentially. Regulations were most stringent, and compliance was greatest, in most of these countries, after the designation of the global pandemic in March and have relaxed to varying degrees in recent months – but cases continued to decline. None of these countries has reported a significant increase in new cases after the peak that would indicate a second wave (although cases in some countries have only recently passed the peak). Together, these observations point to a hypothesis that the outbreaks in these countries have reached herd immunity, and that the recently observed declines in new cases are because many people have already been infected and are immune – at least temporarily.

Figure 2. COVID-19 reported cases in 11 selected low- and middle-income countries, together with best-fit curves from simple disease spread model. Blue circles show daily reported new cases of COVID-19 (based on a 7-day rolling average). Red squares (joined by straight lines) show best-fit outputs from linearized Reed-Frost model.



However, the numbers of cases in other countries – including most high-income countries (HICs) but also some LMICs – show patterns that are much different. Figure 3 shows 7-day rolling averages of reported cases for 6 such comparison countries. In these countries, cases have evolved in a manner that is similar to the first part of the blue curve of Figure 1. There have been peaks in numbers of reported cases, yet the decline is often longer and slower than the red or green curves would suggest. In some countries, there have been resurgences in cases, indicating that the initial suppression was not due to high levels of immunity.

Figure 3. COVID-19 reported cases in 6 selected comparison countries, together with best-fit curves from test of simple disease outbreak model. Blue and brown circles show daily reported new cases of COVID-19 (based on a 7-day rolling average). Red squares (joined by straight lines) show best-fit outputs from linearized Reed-Frost model, fit only to the blue circles in the first peaks in cases.



Fit with disease outbreak model and estimation of outbreak parameters

We test our hypothesis of herd immunity in these 11 countries by using a simple disease outbreak model and fitting to the reported cases. The outbreak case curves are those described by a linearised Reed-Frost model³, the textbook deterministic mathematical model for an epidemic. The curves produced by this model depend on just two parameters, namely the effective basic reproduction number (R_{0_e}) and the mean generation time (t_g), which is the average time from infection of one person and when that person infects other people. Expected reported cases are calculated by scaling the Reed-Frost model's results by a detection rate (p)⁴. The parameters that produce the best-fit curve for reported cases in each country are determined partly analytically from the observed data and partly from least squares regression. Our model parameters (R_{0_e} , t_g and p) are constant over time – a beneficial

assumption in that it avoids having too many free parameters, which might lead to good fits even if the model incorrectly describes the disease dynamics. Furthermore, in most of the countries studied, reported cases and reported deaths have followed similar trends (with changes in deaths lagging the corresponding changes in cases), even for countries with very low absolute numbers of reported cases and deaths – which suggests that the shapes of the curves likely reflect trends in actual cases and deaths, and that detection rates for both do not vary wildly over time.

The best-fit curves are shown with red lines in Figure 2, for each of the 11 LMICs studied, and the corresponding parameters are presented in Table 1 (overleaf). For South Africa, R_{0_e} and t_g are calculated from the slopes and width of the observed data, and p is calculated from the total population, the expected infection rate at the peak (i.e., the herd immunity threshold), and the sum of observed cases up to the peak. For the other 10 countries, we use the value of t_g calculated for South Africa, and determine R_{0_e} and p from fitting to the observed case data. The fits are close, with R-squared goodness-of-fit measures between 0.94 and 1.00. (The fits are somewhat less good for Central African Republic and Malawi, due to very low numbers of reported cases, and for Pakistan, due to undulations in reported cases which may signal variations in R_{0_e} or p which the model assumes are constant.) These results demonstrate that the observed case patterns can indeed very accurately be described by an exponential outbreak halted by herd immunity.

Table 1 presents best estimates for R_{0_e} , p and the infection rate (on 7 September), together with ranges of possible values (in parentheses). There are fairly wide ranges of reasonably possible values because the effects of R_{0_e} and t_g on the observed case curves are hard to distinguish – especially when the observed data has more “noise” or when the observed data does not include many points after the peak, and when values of R_{0_e} are close to 1⁷. For South Africa, R_{0_e} has a best-estimate value of 1.74 (and a range of possible values between 1.45 and 1.90); the corresponding value of t_g is 7.8 days (4.8 days – 9.1 days) and of p is 1.41% (1.93% – 1.27%). For the other 10 countries, we determine best estimates of R_{0_e} and p by assuming that $t_g = 7.8$ days and fitting model outputs to reported cases data. The value of $t_g = 7.8$ days is consistent with studies of serial intervals – the time between illness onset in successive cases in a transmission chain, whose mean value should equal the mean generation time t_g – by Ali *et al.* and others⁸, and close to the values used in other COVID-19 models⁹. We also conduct sensitivity analyses, determining ranges of possible values of R_{0_e} and p if t_g varies between 3 days and 11 days (wider than the range of possible values suggested in the literature^{8,9}), and finding the values of R_{0_e} and p that produce the best fits to the reported cases for the extreme values of t_g . For all of the possible values of t_g , and corresponding values of R_{0_e} and p , the reported case curves generated do not change much, for each of the countries, and lead to the same implication that total infections in the countries are above herd immunity threshold levels (which vary depending on the value of R_{0_e}).

Table 1. Outbreak parameters for selected countries – effective basic reproduction number ($R_{0,e}$), mean generation time (t_g) and case detection rate (p) – and implied share of population infected as of 7 September. The best estimates for the parameters correspond to the best-fit curves shown in Figure 2, and ranges of possible values for each parameter are given in parentheses (and as discussed in the text, are generated by letting t_g vary from 3 days to 11 days). The share of population infected up to 7 September is determined from the model outputs. The table also shows the values of the goodness-of-fit measure R-squared for the best-fit curves in Figure 2.

Country	Effective basic reproduction number ($R_{0,e}$)	Mean generation time (t_g)	Detection rate (p)	Share of population infected up to 7 Sept	R-squared for best-fit curve in Fig. 2 [perfect fit = 1]
Afghanistan	1.7 (1.2–2.1)	7.8 days (3 days – 11 days) [central estimate taken from calculated value for South Africa and supported by other research; range based in part on other research; see text for further discussion]	0.13% (0.26%–0.12%)	71% (37%–82%)	0.97
Bolivia	1.4 (1.1–1.6)		2.35% (5.20%–1.90%)	45% (20%–57%)	0.99
Central African Republic	1.8 (1.3–2.2)		0.13% (0.25%–0.12%)	74% (39%–86%)	0.94
Colombia	1.5 (1.2–1.7)		2.86% (6.24%–2.35%)	46% (21%–58%)	1.00
Egypt	1.6 (1.2–1.9)		0.15% (0.30%–0.13%)	64% (32%–77%)	0.98
Kenya	1.7 (1.2–2.0)		0.09% (0.19%–0.08%)	66% (33%–77%)	0.98
Madagascar	2.0 (1.3–2.4)		0.07% (0.12%–0.06%)	79% (44%–89%)	0.96
Malawi	1.6 (1.2–1.9)		0.05% (0.09%–0.04%)	64% (32%–77%)	0.94
Namibia	1.7 (1.2–2.1)		2.04% (3.89%–1.75%)	71% (37%–83%)	0.97
Pakistan	1.6 (1.2–2.0)		0.20% (0.38%–0.16%)	66% (34%–80%)	0.95
South Africa	1.7 (1.5–1.9)	7.8 days (4.8–9.1 days)	1.41% (1.93%–1.27%)	71% (55%–77%)	0.98

The effective basic reproduction numbers, $R_{0,e}$, in Table 1 range between 1.4 (in Bolivia) and 2.0 (in Madagascar). Estimates for the basic reproduction number, R_0 , the “natural” rate in the absence of social distancing, for SAR-CoV-2 (the virus that causes COVID-19) in Wuhan at the outset of the global epidemic, range from 1.4⁵ up to 5.7⁶. R_0 might be expected to be higher in low-income countries due to factors such as dense living conditions, lack of access to clean water and sanitation facilities, and inability of most people to work from home. Thus, our findings suggest that, for the 11 LMICs studied, social distancing measures and practices likely reduced the effective basic reproduction number and slowed the spread of the disease – but with $R_{0,e}$ above 1, they did not “crush the curve”.

Detection rates are estimated to be very low, ranging from 2.86% in Colombia to 0.05% in Malawi. These low detection rates explain how herd immunity could be reached despite low numbers of reported cases, relative to total population, in all the countries studied. These low detection rates are not surprising. Serological testing results in Kenya, Pakistan and South Africa suggest that the number of

people with coronavirus antibodies substantially exceeds the reported cases – by factors of up to 500 in Kenya (based on data in mid-May)¹⁰, of up to 370 in Pakistan (based on data from May to July)¹¹ and of 20-40 in South Africa (based on data in August)¹², which would correspond to detection rates of 0.2% for Kenya, 0.27% for Pakistan and 2.5-5.0% for South Africa. Furthermore, there is evidence that serological tests might underestimate infection rates and immunity by up to a factor of 2, because more people develop T-cell-mediated immunity than show antibodies¹³.

In all these countries, the analysis indicates that significant percentages of population has been infected and has become immune – at least temporarily. The best estimates of total infection rates on 7 September derived from the fitted curves range from 45% in Bolivia to 79% in Madagascar¹⁴. Note that the infection rates required for herd immunity normally quote the percentage of population infected at the peak of the curve, but significant numbers of people continue to be infected after this point, even as the numbers of new cases decline.

The infection fatality ratio (IFR), or the percentage of deaths from COVID-19 among those infected with the SARS-CoV-2 virus, can be estimated for countries with reliable estimates of deaths. For Bolivia, Colombia and South Africa¹⁵, the IFRs calculated from reported deaths divided by the total number of infections derived from our analysis, are 0.15%, 0.10% and 0.04%, respectively. In these three countries, estimates have been made of excess deaths due to natural causes, and, if all of these excess deaths are due to COVID-19, the IFRs for the three countries could be up to 0.57%, 0.13% and 0.11%, respectively¹⁶. All three countries are expected to have a lower overall IFR, compared to European countries, because their populations have a higher share of young people, who are significantly less likely to die from COVID-19 if they contract the virus. Differences in population age profiles explain the estimated IFR for Bolivia, but not for Colombia or South Africa. If reported infection fatality ratios by age, based on data from several HICs¹⁷, are valid for these countries, the expected overall IFRs for Bolivia, Colombia and South Africa would be 0.57%, 0.63% and 0.33%, respectively. Possible explanations for why mortality risk for COVID-19 might be lower in Colombia or South Africa, compared to the (mainly) European countries from which IFRs by age are derived, could include differences in immune-system response (already observed, for example, between men and women in some HICs), partial immunity to COVID-19 due to prior exposure to other coronaviruses, differences in lethality and prevalence of different virus strains, and different infection rates for different age groups.

To test the robustness of our approach, we applied the same methodology to fit curves to the first peaks in the comparison countries shown in Figure 3 (represented as red lines in this figure). Researchers at Imperial College London and others argued convincingly in June that European countries have not reached herd immunity¹⁸, and subsequent increases in cases have proven their point. Applying our model to fit curves just to the first peaks (shown with blue circles in Figure 3)¹⁹, and hence assuming that the peaks were due to herd immunity, we find that the best-fit curves match the observed data for the first peaks fairly well in all cases, but with values for the disease parameters that are implausible. For example, for France, the best-fitting curve yields $R_{0,e} = 1.4$, $t_g = 3$ days (the lowest permitted value) and $p = 0.39\%$. The detection rate well below the detection rates of between 7% and 20% suggested by serological studies in European countries²⁰. New Zealand is well-known for “crushing” the curve – and the parameters associated with the best-fit “herd immunity curve” to its reported cases would be $R_{0,e} = 1.9$, $t_g = 3$ days and a highly improbable $p = 0.03\%$. Thus, our approach leads to a conclusion for the comparison countries that the evolution of reported cases was not due to herd immunity (but instead must have been due to control measures). With this check, we increase our confidence in the hypothesis that the outbreaks in the 11 LMICs studied are declining due to herd immunity, which generates well-fitting curves with plausible parameters.

Discussion

Prominent models of the epidemic from teams at Imperial College London (ICL)²¹ and the University of Washington Institute for Health Metrics and Evaluation (IHME)²² use SEIR simulations and determine key parameters – especially the effective reproduction number, which can vary over time – by fitting the models' results for deaths to the reported numbers of deaths from COVID-19 and utilising age-specific IFRs from recent studies (in HICs). These models estimate that total infections to date for the 11 LMICs we studied are much greater than reported, but much smaller than our analysis suggests. For example, the models estimate total infection rates for South Africa of 7.7% (ICL) and 9.5% (IHME)²³ – significantly lower than the rates of between 20% and 40% suggested by the recently announced serological study findings²⁴ – and detection rates of 13.9% and 11.2% respectively. It has previously been observed, by the IHME COVID-19 Model Comparison Team, that the predictive performance of seven COVID-19 models, including those of ICL and IHME, shows significantly higher errors for Sub-Saharan Africa, South Asia and Latin America and the Caribbean, compared to their performance for HICs²⁵. Our research suggests why this might be the case. The ICL, IHME and other models are well-suited to HICs: reported deaths for such countries are likely to be reasonably close to actual deaths; the IFRs used in the models are based mainly on studies conducted in HICs; and it is clear from the evolution of reported cases that these countries have not reached herd immunity²⁶ and that their effective basic reproduction numbers have varied significantly over time as disease control measures have been introduced and adjusted (necessitating the additional granularity of SEIR modelling). However, for some LMICs: reported deaths from COVID-19 are likely to understate actual deaths by large factors; age-specific IFRs might differ substantially from those in Europe and North America; and a simple model, using the approximation that effective basic reproduction numbers and detection rates remain constant over time, may be sufficient to describe the evolution of reported cases well (at least for the 11 countries we studied).

Systematic studies of representative population samples should be conducted in each of the 11 LMICs discussed here, to determine the percentages of people who have been infected and are immune – and consequently test directly the primary conclusion that the overall infection rates are very high and exceed estimated herd immunity thresholds. Serological studies are ongoing in some counties, such as South Africa. However, these studies may still underestimate infection and immunity levels, because people may have immunity driven by T-cells without detectable antibodies²⁷. However, it is unclear whether the presence of T-cells provides complete immunity and T-cell immunity is harder to determine than antibodies in blood.

Herd immunity means that the virus can no longer spread uncontrollably, but not that it is gone completely. Individuals may still contract the virus if they are not immune. Isolated communities, such as rural areas far from urban centers, may have much lower infection rates than the overall population, and may still experience localised outbreaks. New general outbreaks might happen as control measures are relaxed, and such outbreaks could be large for countries where $R_{0,e}$ is currently close to 1 and/or for which cases have not mostly declined from the (current) herd immunity peak – because relaxing disease control measures will increase $R_{0,e}$ and could shift the herd immunity threshold (which is $1 - 1/R_{0,e}$) to new values that are substantially greater than the current share of the population with immunity.

It is not yet known how long immunity from SARS-CoV-2 lasts. Even if a population has herd immunity today, it is possible that this could be lost over time, which might lead to future outbreaks – the severity of which would depend on the share of people losing immunity, the amount of variation in timing of when people lose immunity, and whether susceptibility to reinfection is equal to the susceptibility to first infection. New strains of SARS-CoV-2 have emerged, and it is conceivable that future mutations could allow the virus to evade immune systems, and thus render previously immune populations susceptible again to the disease – but there is no evidence yet of any such immunity-evading strains.

References and Notes

1. See <https://www.imperial.ac.uk/news/195976/individual-response-covid-19-important-government-action/>.
2. Three distinct reproduction numbers characterise the disease in different situations. First, the basic reproduction number, R_0 , is the average number of new infections caused by each current infected individual, that would happen in the absence of any disease control measures by governments or individuals, and before there is widespread immunity. Even this number is not a universal characteristic, because it can vary by location, even in the absence of control measures, due to differences in typical numbers of social contacts in different places. Second, we define the effective basic reproduction number, $R_{0,e}$, as the adjusted basic reproduction number after control measures are taken, but without significant levels of immunity. This number can, therefore, change from time to time, as governments change policies and people change their practices. Third, the effective reproduction number, R_e , is the actual average number of new infections caused by each current infected individual, which decreases as the number of people with immunity increases (and also depends on disease control policies and practices).
3. See, for example, Kenneth J. Rothman, *Epidemiology*, Ch. 6, or other textbooks on epidemiology. Our linearized version of the Reed-Frost model uses the formula $n_{i+1} = n_i * R_{0,e} * s_i / n_{tot}$, where n_i is the number of infected people for the time period i , s_i is the number of susceptible people without immunity for the time period i , and n_{tot} is the total population. The mean generation time t_g is the duration of each time period in the model. Expected reported cases are equal to $p * n_i$ for each time step i in the model, where p is the case detection rate.
4. One more parameter is required in fitting the curve, namely the difference between the actual first case and the first reported case. This parameter can only shift the model curve to earlier or later times, without changing the shape of the curve and without impacting any of the other parameters.
5. J Riou and CL Althaus, "Pattern of early human-to-human transmission of Wuhan 2019-nCoV," *Euro Surveill* 2020;25(4):pii=2000058. <https://doi.org/10.2807/1560-7917.ES.2020.25.4.2000058>
6. S Sanche et al., "High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2," *Emerg Infect Dis*. 2020;26(7):1470-1477. <https://dx.doi.org/10.3201/eid2607.200282>
7. For a given shape of the curve of disease cases over time – characterised by the exponential rates of increase before the peak and of decrease after the peak and the width of the curve – there is a unique combination of $R_{0,e}$ and t_g which leads to the observed curve. However, for any given curve, there are a range of combinations of $R_{0,e}$ and t_g which can produce very similar curves. (This issue is why it is very hard to determine the basic reproduction number, R_0 , for any new disease, even when the case doubling time is well-known.) In the case of South Africa, the observed data is sufficiently "clean" that we are able to calculate $R_{0,e}$ and t_g . For the other countries, the observed data is more "noisy" or does not have much data after the peak, and there can be multiple combinations of $R_{0,e}$ and t_g which produce reasonable fits to the observed data.
8. ST Ali, L Wang, EHY Lau et al., "Serial interval of SARS-CoV-2 was shortened over time by nonpharmaceutical interventions," *Science*, 28-08-2020, doi: <https://doi.org/10.1126/science.abc9004>, finds, from data on transmission pairs in mainland China in January and February 2020, that the mean serial interval was 7.8 days early in the

epidemic but shortened substantially to 2.6 days within a month. J. M. Griffin et al., “A rapid review of available evidence on the serial interval and generation time of COVID-19”, medRxiv 2020.05.08.20095075, 11 May 2020, <https://doi.org/10.1101/2020.05.08.20095075>, found 22 estimates for the mean serial intervals between 3.1 and 7.5 days, and 3 estimates of the mean generation time between 3.9 and 5.2 days. Studies of serial intervals and mean generation time rely on symptomatic cases identified within health systems, and Ali et al. find that early case isolation decreases the mean serial interval. Therefore, it is reasonable to assume that the mean generation time, equal to the mean serial interval, for complete populations should be greater than those reported in the literature. The best estimate for t_g calculated from the reported cases curve in South Africa, namely 7.8 days, is the same value as the mean serial interval in the early days of the epidemic in China reported by Ali et al., and is a reasonable value to use for in our model for the other 10 LMICs that we consider. For the sensitivity analysis, we use a range of t_g from 3 to 11 days, which is wider than the full range of possible values of the mean generation time suggested in the literature to date.

9. For example, the Imperial College London team’s models assume a gamma-distributed serial interval with mean 6.48 days and standard deviation of 3.83 days. See <https://mrc-ide.github.io/covid19-short-term-forecasts/index.html> and NM Ferguson et al. “Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand”. 16 March 2020 Imperial College COVID-19 Response Team,” <https://doi.org/10.25561/77482>.
10. KEMRI/Wellcome Trust, Preliminary Report of SARS-CoV-2 antibody prevalence among blood donors in Kenya, 28 June 2020.
11. S Zaidi et al. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi—challenges in acquiring herd immunity for COVID 19, *Journal of Public Health*, fdaa170, <https://doi.org/10.1093/pubmed/fdaa170>.
12. Announced by Dr. Zweli Mkhize, Minister for Health of South Africa, as reported by AP: <https://apnews.com/cffcd4dfb1e3cbd810838fb9bde7a91d>.
13. T Sekine et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell* (2020), doi: <https://doi.org/10.1016/j.cell.2020.08.017>.
14. All numbers apply to the portion of a country that has had some level of exposure. If specific physically concentrated groups in a country are fully shielded, the total proportion of the national population that has been infected to date, would be lower than the numbers listed here. For most countries, the numbers are as of 7 September; for some, they are as of 5 or 6 September.
15. The other countries studied have not reported excess mortality, and are likely under-report deaths from COVID-19 significantly, and by differing proportions in each country. As a result, we limit our estimates of IFRs to the cases of Bolivia, Colombia and South Africa.
16. For all three countries, we use reported deaths as of 21 September. We estimate the IFRs expected if all excess deaths from natural causes are due to COVID-19, from the ratios of excess deaths to reported deaths as of the dates for which estimates of excess deaths are available. For Bolivia, as of 31 August, reported deaths due to COVID-19 were 5,027 and underreported deaths attributed to COVID-19 were 14,508, according to the Servicio de Registro Cívico (SERECI) (as reported in <https://muywaso.com/14-mil-muertes-que-no-se-pueden-ocultar-y-una-tasa-de-subregistro-del-75/>). For Colombia, from 18 May to 2 August, reported deaths due to COVID-19 were 12,393 and total excess deaths were 15,728, as reported by Minsalud

- (<https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/VS/ED/VSP/estimacion-exceso-mortalidad-colombia-covid19.pdf>). For South Africa, reported deaths due to COVID-19 were 15,499 as of 15 September, while excess deaths due to natural causes (which may not all be due to COVID-19 but are assumed to be for this calculation) between 6 May and 15 September are estimated to be 44,481 by the South African Medical Research Council (SAMRC) (<https://www.samrc.ac.za/reports/report-weekly-deaths-south-africa?bc=254>).
17. AT Levin et al. "Assessing the Age Specificity of Infection Fatality Rates for COVID-19: Meta-Analysis & Public Policy Implications" - medRxiv 2020.07.23.20160895
doi: <https://doi.org/10.1101/2020.07.23.20160895>.
 18. LC Okell, R Verity, OJ Watson et al. Have deaths from COVID-19 in Europe plateaued due to herd immunity? The Lancet; 11-06-2020, doi: [https://doi.org/10.1016/S0140-6736\(20\)31357-X](https://doi.org/10.1016/S0140-6736(20)31357-X).
 19. The fits are made to only the first 100 days of reported cases for each of France, Germany and Spain, the first 150 days of reported cases for the United Kingdom, and the first 75 days of reported cases for China and New Zealand.
 20. Calculated by comparing findings from seroprevalence studies in England (H Ward, CJ Atchison, M Whitaker et al. Antibody prevalence for SARS-CoV-2 in England following first peak of the pandemic: REACT2 study in 100,000 adults. *medRxiv* 2020: 2020.08.12.20173690), Italy (Italy National Institute of Statistics. Primi risultati dell'indagine di sieroprevalenza sul SARS-CoV-2. 2020), Portugal (Portugal National Institute of Health. Relatório de Apresentação dos Resultados Preliminares do Primeiro Inquérito Serológico Nacional COVID-19. 2020) and Spain (R Pastor-Barriuso, B Perez-Gomez, MA Hernan et al. SARS-CoV-2 infection fatality risk in a nationwide seroepidemiological study. *medRxiv* 2020: 2020.08.06.20169722) with reported cases from around the times of the studies.
 21. The ICL model is described at <https://mrc-ide.github.io/global-lmic-reports/parameters.html>. See also PT Walker, C Whittaker, OJ Watson et al. The impact of COVID-19 and strategies for mitigation and suppression in low- and middle-income countries. *Science*; 12-06-2020, doi: <https://doi.org/10.1126/science.abc0035>.
 22. The IHME model results are at <https://covid19.healthdata.org/global>. See also J Friedman, P Liu, E Gakidou, and IHME COVID-19 Model Comparison Team. Predictive performance of international COVID-19 mortality forecasting models. *MedRxiv*. 14 July 2020.
doi:10.1101/2020.07.13.20151233.
 23. Derived from the total reported cases divided by the total mean estimates of new infections from the models, up to 8 September, as reported on <https://ourworldindata.org/covid-models>.
 24. Announced by Dr. Zweli Mkhize, Minister for Health of South Africa, as reported by AP: <https://apnews.com/cffcd4dfb1e3cbd810838fb9bde7a91d>.
 25. J Friedman, P Liu, E Gakidou, and IHME COVID-19 Model Comparison Team. Predictive performance of international COVID-19 mortality forecasting models. *MedRxiv*. 14 July 2020.
doi:10.1101/2020.07.13.20151233.
 26. LC Okell, R Verity, OJ Watson et al. Have deaths from COVID-19 in Europe plateaued due to herd immunity? The Lancet; 11-06-2020, doi: [https://doi.org/10.1016/S0140-6736\(20\)31357-X](https://doi.org/10.1016/S0140-6736(20)31357-X).
 27. T Sekine et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell* (2020), doi: <https://doi.org/10.1016/j.cell.2020.08.017>.

Acknowledgements

We wish to thank Muhannad Alramlawi and Yohann Sequeira for help with parts of the modelling and research. We also acknowledge many useful discussions with Partners and consultants at Dalberg Advisors, in particular Edwin Macharia.

Funding: No funding was received to support this work.

Author contributions: A.S.L. conceived the first analysis of South Africa data, and J.P.C. conceived the idea to study a range of LMICs and comparator countries. A.S.L., C.J.A.N. and O.F. undertook the modelling. J.P.C. conducted the comparison of model parameters and assumptions with other research and with other epidemiological models. J.P.C. and C.J.A.N. prepared the manuscript.

Competing interests: C.J.A.N., O.F., J.P.C. work at Dalberg Advisors, a management consultancy whose clients include multilateral agencies, foundations, international development agencies, governments, companies and NGOs. C.J.A.N., O.F. and J.P.C. have prepared this article in a personal capacity, and the work was not funded by any client of Dalberg Advisors.

Data and materials availability: All data used in this study can be freely downloaded from the cited sources. The supplementary materials provide additional details on methods, including the equations used and the process for determining the parameters, and other notes and observations.

Supplementary Materials

A document with supplementary materials, including methods and other notes, is attached.